Hepion Pharmaceuticals (HEPA) Competitors $0.17 -0.02 (-9.04%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$0.17 0.00 (-2.34%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends HEPA vs. ALLR, UPXI, MAAQ, SYRS, ATNF, ARTL, GRI, PLRZ, BPTH, and SNOAShould you be buying Hepion Pharmaceuticals stock or one of its competitors? The main competitors of Hepion Pharmaceuticals include Allarity Therapeutics (ALLR), Upexi (UPXI), Mana Capital Acquisition (MAAQ), Syros Pharmaceuticals (SYRS), 180 Life Sciences (ATNF), Artelo Biosciences (ARTL), GRI Bio (GRI), Polyrizon (PLRZ), Bio-Path (BPTH), and Sonoma Pharmaceuticals (SNOA). These companies are all part of the "pharmaceutical products" industry. Hepion Pharmaceuticals vs. Allarity Therapeutics Upexi Mana Capital Acquisition Syros Pharmaceuticals 180 Life Sciences Artelo Biosciences GRI Bio Polyrizon Bio-Path Sonoma Pharmaceuticals Allarity Therapeutics (NASDAQ:ALLR) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, community ranking, dividends and earnings. Which has stronger valuation & earnings, ALLR or HEPA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllarity TherapeuticsN/AN/A-$11.90MN/AN/AHepion PharmaceuticalsN/AN/A-$48.93M-$4.38-0.04 Is ALLR or HEPA more profitable? Allarity Therapeutics' return on equity of -369.67% beat Hepion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Allarity TherapeuticsN/A -369.67% -100.06% Hepion Pharmaceuticals N/A -812.56%-207.31% Which has more volatility & risk, ALLR or HEPA? Allarity Therapeutics has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Do insiders and institutionals hold more shares of ALLR or HEPA? 11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 0.1% of Allarity Therapeutics shares are owned by insiders. Comparatively, 4.7% of Hepion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media favor ALLR or HEPA? In the previous week, Allarity Therapeutics had 1 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 1 mentions for Allarity Therapeutics and 0 mentions for Hepion Pharmaceuticals. Hepion Pharmaceuticals' average media sentiment score of 0.00 beat Allarity Therapeutics' score of -0.31 indicating that Hepion Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Allarity Therapeutics Neutral Hepion Pharmaceuticals Neutral Does the MarketBeat Community favor ALLR or HEPA? Hepion Pharmaceuticals received 20 more outperform votes than Allarity Therapeutics when rated by MarketBeat users. Likewise, 67.74% of users gave Hepion Pharmaceuticals an outperform vote while only 50.00% of users gave Allarity Therapeutics an outperform vote. CompanyUnderperformOutperformAllarity TherapeuticsOutperform Votes150.00% Underperform Votes150.00% Hepion PharmaceuticalsOutperform Votes2167.74% Underperform Votes1032.26% SummaryHepion Pharmaceuticals beats Allarity Therapeutics on 6 of the 10 factors compared between the two stocks. Get Hepion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HEPA vs. The Competition Export to ExcelMetricHepion PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19M$7.04B$5.77B$8.99BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-0.046.1326.4618.82Price / SalesN/A311.22453.6978.73Price / CashN/A67.8344.0437.47Price / Book0.136.747.634.64Net Income-$48.93M$138.11M$3.18B$245.69M7 Day Performance-6.61%-2.43%-1.91%-2.66%1 Month Performance26.67%-1.91%-0.19%-2.15%1 Year Performance-93.02%-5.03%16.70%12.90% Hepion Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HEPAHepion Pharmaceuticals0.1494 of 5 stars$0.17-9.0%N/A-92.4%$1.19MN/A-0.0420Gap DownALLRAllarity Therapeutics0.561 of 5 stars$1.05-3.7%N/A-99.6%$4.65MN/A0.0010UPXIUpexi0.7097 of 5 stars$3.68-6.1%$25.00+579.3%-80.4%$4.56M$26M0.00130Earnings ReportMAAQMana Capital AcquisitionN/A$0.56+23.0%N/A-72.6%$4.54MN/A0.001High Trading VolumeSYRSSyros Pharmaceuticals4.243 of 5 stars$0.17-3.2%$3.33+1,890.0%-97.5%$4.49M$386,000.00-0.06120ATNF180 Life SciencesN/A$1.38-1.4%N/A-65.6%$4.39MN/A0.007Analyst ForecastNews CoveragePositive NewsARTLArtelo Biosciences3.1843 of 5 stars$1.35+1.5%$5.50+307.4%-27.5%$4.36MN/A-0.475News CoverageGap DownGRIGRI Bio2.3672 of 5 stars$0.48+0.4%$11.50+2,290.9%-96.7%$4.30MN/A0.001Stock SplitNews CoveragePLRZPolyrizonN/A$1.02-8.9%N/AN/A$4.27MN/A0.00N/AGap DownBPTHBio-Path2.4742 of 5 stars$0.74-5.8%$20.00+2,617.4%-97.9%$4.25MN/A0.0010Analyst ForecastSNOASonoma Pharmaceuticals0.201 of 5 stars$2.61-1.9%N/A+1,447.9%$4.22M$13.97M-0.65180Negative News Related Companies and Tools Related Companies ALLR Alternatives UPXI Alternatives MAAQ Alternatives SYRS Alternatives ATNF Alternatives ARTL Alternatives GRI Alternatives PLRZ Alternatives BPTH Alternatives SNOA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HEPA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HEPA Stock Alerts